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OBJECTIVES: Hyperuricemia is a risk factor for contrast-induced acute kidney injury in patients with chronic
kidney disease. This study evaluated the value of hyperuricemia for predicting the risk of contrast-induced
acute kidney injury in patients with relatively normal serum creatinine who were undergoing percutaneous
coronary interventions.
METHODS AND RESULTS: A total of 788 patients with relatively normal baseline serum creatinine (,1.5 mg/dL)
undergoing percutaneous coronary intervention were prospectively enrolled and divided into a hyperuricemic
group (n=211) and a normouricemic group (n=577). Hyperuricemia is defined as a serum uric acid level.7 mg/
dL in males and .6 mg/dL in females. The incidence of contrast-induced acute kidney injury was significantly
higher in the hyperuricemic group than in the normouricemic group (8.1% vs. 1.4%, p,0.001). In-hospital
mortality and the need for renal replacement therapy were significantly higher in the hyperuricemic group.
According to a multivariate analysis (adjusting for potential confounding factors) the odds ratio for contrast-
induced acute kidney injury in the hyperuricemic group was 5.38 (95% confidence interval, 1.99-14.58;
p=0.001) compared with the normouricemic group. The other risk factors for contrast-induced acute kidney
injury included age .75 years, emergent percutaneous coronary intervention, diuretic usage and the need for
an intra-aortic balloon pump.
CONCLUSION: Hyperuricemia was significantly associated with the risk of contrast-induced acute kidney injury
in patients with relatively normal serum creatinine after percutaneous coronary interventions. This observation
will help to generate hypotheses for further prospective trials examining the effect of uric acid-lowering
therapies for preventing contrast-induced acute kidney injury.
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& INTRODUCTION
Contrast-induced acute kidney injury (CI-AKI) has been
recognized as a serious complication of percutaneous
coronary intervention (PCI) and may cause an increase in
morbidity and mortality (1,2). In addition to prophylactic
intravenous volume expansion with isotonic crystalloid
solution (3), few prophylactic strategies for CI-AKI are
clearly effective. A key step in minimizing the risk of CI-AKI
is identifying at-risk patients.
Many risk factors, such as pre-existing renal dysfunction,
exposure to a high volume of contrast medium, older age,
hypovolemia, congestive heart failure, emergent PCI, and
exposure to nephrotoxic drugs, have been associated with
developing CI-AKI (4-7). Currently, the most widely
recognized risk factor for developing CI-AKI is baseline
renal impairment, which is conventionally defined as a
serum creatinine (SCr) level$1.5 mg/dL (132 mmol/dL)
(5,8). Few studies have investigated patients with normal
renal function, although these patients constitute the
majority of those undergoing PCI. CI-AKI prophylaxis,
including hydration, is not typically administered to
patients with normal baseline SCr (,1.5 mg/dL).
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The relationship between hyperuricemia (HUA) and CI-
AKI has not been extensively studied. It has been suggested
that tubular obstruction by uric acid plays a role in the
pathogenesis of CI-AKI (9,10). HUA is accompanied by
enhanced synthesis of reactive oxygen species, activation of
the renin–angiotensin–aldosterone system, an increase in
endothelin-1, and inhibition of the nitric oxide system; all of
these factors play a role in the pathogenesis of CI-AKI (11-13).
Toprak et al. observed that HUA was a risk factor for CI-
AKI in patients undergoing coronary angiography with
chronic kidney disease (SCr$1.2 mg/dL) (14). We aim to
identify the risk predictors in this cohort and evaluate the
value of HUA in predicting the risk of CI-AKI in patients




We conducted a prospective, controlled single-center
observational study at Guangdong Cardiovascular Ins-
titute, Guangdong General Hospital, Guangdong Academy
of Medical Sciences between February 2010 and January
2011. The exclusion criteria were pregnancy, lactation,
sepsis, the intravascular administration of a contrast
medium within the past seven days, nephroprotective drug
treatment (e.g., N-acetylcysteine, theophylline, prostaglan-
din E1, sodium bicarbonate), nephrotoxic drug intake (e.g.,
non-steroidal anti-inflammatory drugs, metformin, amino-
glycosides, amphotericin B, cisplatin) within the past seven
days, a history of serious reactions to contrast media, renal
transplantation, end-stage renal disease necessitating dia-
lysis, and severe concomitant disease of other systems. We
also excluded the patients who died during PCI or who had
hemodynamic instability requiring an intra-aortic balloon
pump (IABP) before PCI. The Ethics Committee of the
Guangdong General Hospital approved the study. All of the
eligible patients provided written informed consent.
Study protocol
We screened 960 patients who underwent PCI. A total of
788 patients met the inclusion criteria. The eligible patients
were divided into two groups: hyperuricemic (n = 211) and
normouricemic (n = 577). As in previous studies (15,16),
HUA was defined as a serum uric acid level.7 mg/dL
(417 mmol/L) in males and.6 mg/dL (357 mmol/L) in
females. None of the patients in the hyperuricemic group
had gout, documented uric acid stones, or any acute HUA
complications (i.e., they had asymptomatic HUA).
Left ventricular function was evaluated with echocardio-
graphy in all of the patients within 24 h of admission. The
patients were hydrated with intravenous isotonic saline
(0.9%) at a rate of 1 mL/kg body weight per h for 1-8 h
before and 6-8 h after PCI. In the patients with left
ventricular ejection fraction (LVEF) ,40% or overt heart
failure, the hydration rate was reduced to 0.5 mL/kg per h.
PCI was performed with a low-osmolar, non-ionic contrast
medium (LOCM). The PCI operations and the use of an
IABP, inotropic drugs, tirofiban, beta-blockers, angiotensin-
converting-enzyme inhibitors, and diuretics were left to the
discretion of the cardiologists.
The primary endpoint of the study was the occurrence of
CI-AKI, which was defined as an increase in serum
creatinine of$0.5 mg/dL above the baseline value within
48-72 h after PCI (17,18). We obtained the blood samples
used to measure preoperative serum uric acid, baseline
serum creatinine (SCr) (prior to the pre-procedural hydra-
tion), blood urea nitrogen (BUN), random blood glucose,
electrolytes before PCI, serum lipids, fasting blood glucose,
albumin, hemoglobin, and other standard clinical para-
meters after an 8-h overnight fast. Follow-up SCr and BUN
levels were measured one, two, and three days after the
procedure (19% of the patients stayed in the hospital for
three days and participated in the sampling on day 3).
Baseline creatinine clearance was calculated with the Cock-
Croft–Gault formula: (140-age)6weight (kg)/SCr (mg/
dL)726(0.85 for females) (19). The major in-hospital clinical
event (e.g., death) was recorded at the same time.
Statistical analysis
SPSS software for Windows (version 13.0, SPSS Inc.,
Chicago, Illinois, USA) was used for the analyses. The
demographics and traditional risk factors were compared
between the hyperuricemic and normouricemic groups. All
of the values are expressed as the mean¡SD or medians
and interquartile ranges. The differences between the means
were compared with an unpaired t-test for the variables that
were normally distributed and with the Mann-Whitney U-
test for the variables that were not normally distributed.
Categorical variables were analyzed using the x2 test. We
performed logistic regression analysis with CI-AKI as the
dependent variable. The variables that were statistically
significant according to the univariate analysis were
included in the final multivariate model to identify the CI-
AKI predictors. A two-sided 95% confidence interval (CI)
was constructed around the point estimate of the odds ratio
(OR). All of the tests were two-sided, and a p-value,0.05
was considered statistically significant.
& RESULTS
A total of 788 patients were enrolled in the study. Based
on their serum uric acid concentrations, 211 patients were
assigned to the hyperuricemic group and 577 to the
normouricemic group (mean serum uric acid 481¡72 and
310¡66 mmol/L, respectively, p,0.001); mean age (65¡12
and 62¡11, respectively, p,0.001); and proportion of males
(70% and 82%, respectively, p,0.001). The following
demographic, clinical, and angiographic characteristics
were compared between the hyperuricemic and normour-
icemic groups (as shown in Tables 1 and 2): older age (21%
vs. 11%, p,0.001), pre-existing renal dysfunction (48% vs.
29%, p,0.001), serum cholesterol levels (total cholesterol
4.77¡1.29 vs. 4.56¡1.11 mmol/L, p = 0.024; low-density
lipoprotein cholesterol 3.07¡1.06 vs. 2.92¡0.95, p = 0.055),
severely reduced LVEF (12% vs. 8%, p= 0.061), hypertension
(70% vs. 54%, p,0.001), anemia (22% vs. 16%, p= 0.065),
multivessel coronary disease (79% vs. 69%, p,0.001), the
exposure time to contrast agents, the number of coronary
lesions, and the ratio of smokers to non-smokers were
significantly different between the two groups. There were
no significant differences between the two groups in the
incidence of diabetes mellitus (20% vs. 23%, p = 0.441),
emergent PCI (23% vs. 26%, p = 0.404), contrast amount,
coronary heart disease type, or other parameters.
We determined the CI-AKI risk scores according to
Scheme Model A developed by Mehran et al. (7). The mean
and median CI-AKI risk scores in the hyperuricemic group
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were significantly greater than the scores in the normour-
icemic group (mean 8.1¡4.8, median 7.4, interquartile range
5.8–10.8 vs. mean 6.2¡4.0, median 6.3, interquartile range
1.8–9.2, p,0.001) (Table 2).
Overall, the incidence of CI-AKI was significantly
different (p,0.001) between the two groups; CI-AKI
occurred in 17 (8.1%) members of the hyperuricemic group
and 8 (1.4%) members of the normouricemic group. The
levels of uric acid were significantly higher in the CI-AKI
group than in the group without CI-AKI (448¡131 vs.
353¡99 mmol/L, p=0.001). In-hospital mortality was sig-
nificantly higher in the hyperuricemic group than in the
normouricemic group (2.4% vs. 0.3%, p= 0.007) (Table 3).
Hyperuricemia increased the rates of CI-AKI requiring renal
replacement therapy (1.4% vs. 0%, p= 0.004), IABP therapy
(6.2% vs. 2.8%, p = 0.025), and post-procedural hypotension
(5.3% vs. 1.9%, p= 0.011).
A multivariate analysis (adjusted for other potential
confounding factors, gender, age.75 y, CrCl,60 ml/min,
multivessel coronary disease, emergent PCI, LVEF,40%,
hypertension, diabetes, ACEI/ARB, IABP, exceeding max-
imum contrast dose, anemia, diuretic usage) revealed that
the odds ratio (OR) for CI-AKI in the hyperuricemic group
compared to the normouricemic group was 5.38 (95%
confidence interval [CI], 1.99-14.58, p= 0.001) (Table 4).
Notably, age.75 years (OR: 3.55, 95% CI: 1.21-10.42,
Table 1 - Baseline demographics and clinical characteristics.
Variables Hyperuricemic group (n =211) Normouricemic group (n=577) p-value
Age (y) 65¡12 62¡11 ,0.001
Age.75 y (%) 44 (21) 63 (11) ,0.001
Males (%) 147 (70) 472 (82) ,0.001
Weight (kg) 65¡11 64¡10 0.240
SBP (mmHg) 132¡23 131¡21 0.940
Smokers (%) 87 (41) 267 (46) 0.208
Hypertension (%) 148 (70) 311 (54) ,0.001
Diabetes (%) 42 (20) 130 (23) 0.430
Unilateral/bilateral RAS$50 (%) 7 (3) 17 (3) 0.788
Hyperlipidemia (%) 40 (19) 96 (17) 0.445
Total cholesterol (mg/dl) 4.77¡1.29 4.56¡1.11 0.024
LDL-cholesterol (mg/dl) 3.07¡1.06 2.92¡0.95 0.055
Serum uric acid (mmol/L) 481¡72 310¡66 ,0.001
Coronary heart disease type 0.347
Acute coronary syndrome (%) 193 (92) 539 (93)
Stable angina (%) 18 (8) 38 (7)
Previous MI (%) 24 (11) 73 (13) 0.629
CABG (%) 4 (2) 4 (1) 0.220
LVEF (%) 57¡13 58¡12 0.469
LVEF ,40% (%) 26 (12) 46 (8) 0.061
Emergent PCI (%) 48 (23) 148 (26) 0.404
ACEI/ARB usage (%) 185 (88) 529 (92) 0.088
Diuretic usage 36 (17) 70 (12) 0.073
Baseline SCr (mmol/L) 94¡19 85¡18 ,0.001
CrCl, (mL/min) 65¡24 75¡24 ,0.001
CrCl,60 mL/min, (%) 100 (48) 165 (29) ,0.001
Anemia (%) 46 (22) 93 (16) 0.064
Hypoalbuminemia (%) 28 (13) 67 (12) 0.527
HbAlc (%) 6.5¡1.1 6.5¡1.3 0.876
SBP, systolic blood pressure; RAS, renal artery stenosis; LDL, low-density lipoprotein cholesterol; MI, myocardial infarction; CABG, coronary artery bypass
grafting; LVEF, left ventricular ejection fraction; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker; CrCl, Creatinine
clearance; HbAlc, glycated hemoglobin.
Table 2 - Angiographic and procedural characteristics.
Characteristic Hyperuricemic group (n =211) Normouricemic group (n=577) p-value
Number of diseased vessels 2.3¡0.8 2.1¡0.9 ,0.001
Multivessel coronary disease (%) 167 (79) 398 (69) 0.005
Number of stents used 2.1¡1.3 2.0¡1.2 0.163
Total stent length (mm) 52¡34 47¡32 0.070
Type of LOCM 0.963
Iopamiron (%) 109 (52) 297 (52)
Ultravist (%) 102 (48) 280 (48)
Contrast amount (mL) 156¡69 150¡60 0.256
Exceeding MCD (%) 13 (6) 22 (4) 0.157
Procedure duration of (min) 88¡37 83¡37 0.087
CIN score mean (SD) { 8.1¡4.8 6.2¡4.0 ,0.001
CIN score median (IQR) { 7.4 (5.8-10.8) 6.3 (1.8-9.2) ,0.001
Abbreviations: LOCM, low-osmolar contrast media.
MCD: maximum contrast dose (mL) = (56body weight [kg]) divided by serum creatinine (mg/dL);
{: Scheme (Model A) to define contrast-induced nephropathy (CIN) risk score by Mehran et al. (J Am Coll Cardiol Vol. 44, No. 7, 2004).
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p= 0.021), emergent PCI (OR: 3.66, 95% CI: 1.40-9.55,
p= 0.008), diuretic usage (OR: 4.87, 95% CI: 1.87-12.69,
p= 0.001) and IABP (OR: 7.29, 95% CI: 2.29-23.15, p=0.001)
were retained in the final model.
& DISCUSSION
The main finding of this study, which was the first to
evaluate the value of HUA in predicting CI-AKI develop-
ment in patients with normal baseline SCr after PCI, was
that HUA was a significant and independent predictor of
CI-AKI after PCI and resulted in significantly greater in-
hospital mortality and incidence of CI-AKI requiring renal
replacement therapy after PCI.
Pre-existing renal dysfunction has been known to be the
most important risk factor for CI-AKI. At our institution, the
patients with elevated baseline SCr received sufficient
perioperative CI-AKI prophylaxis following the recent
guidelines by the American College of Cardiology (20)
and the European Society of Cardiology (21). The patients
with normal SCr values, however, did not receive any
prophylaxis, as they are typically thought to be at low risk.
Chong et al. (22) observed that subgroups of patients with
normal baseline SCr who were undergoing PCI were at risk
of developing CI-AKI, which results in higher mortality.
Therefore, despite normal baseline SCr values, the sub-
groups of patients undergoing PCI may be at higher risk of
developing CI-AKI. In our study, we identified several
independent risk predictors of CI-AKI in addition to
baseline renal impairment. These risk predictors include
older age (.75 years), emergent PCI, and IABP therapy.
This is the first study in which HUA has been identified as
an independent risk predictor of CI-AKI. Hence, the
patients with normal baseline SCr values who have the risk
factors discussed above should be considered for additional
renal prophylaxis treatment.
A few studies have shown an association between HUA
and the progression of kidney disease (23,24). Only two
small studies, which investigated the relationship between
the use of contrast agents and uric acid, have observed that
contrast agents had a uricosuric effect that appeared to be
caused by an increase in the renal tubular secretion of uric
acid (25,26). Little information, however, is available in the
literature about the relationship between HUA and the
progression of CI-AKI (9,27).
Toprak et al. (14) conducted the most rigorous observa-
tional study of the value of HUA for predicting the risk of
CI-AKI in patients. The subjects were patients with chronic
kidney disease (SCr$1.2 mg/dL) who were considered at
high risk of developing CI-AKI. They received daily
prophylaxis using a different definition for CI-AKI (an
increase of 25% in creatinine) than the definition that used
in the present study. The patients presented with relatively
normal baseline SCr levels. Our study could be regarded as
an extension of the study by Toprak et al. The results of the
present study were consistent with those obtained by
Toprak and colleagues; the HUA patients were at risk of
developing CI-AKI. Recently, Park et al. (28) also concluded
that HUA was independently associated with an increased
risk of in-hospital mortality and CI-AKI in patients treated
with PCI, although they performed a retrospective analysis
that used a different definition of CI-AKI (an increase in
SCr$0.5 mg/dL or$50% over baseline within seven days of
Table 3 - Hyperuricemia and in-hospital clinical complications.
Complication Hyperuricemic group (n=211) Normouricemic group (n=577) p-value
CI-AKI (%) 17 (8.1) 8 (1.4) ,0.001
Death (%) 5 (2.4) 2 (0.3) 0.007
Cause of death 0.001
Cardiogenic shock (%) 0 1 (0.2)
Cardiac rupture (%) 1 (0.5) 1 (0.2)
Arrhythmia (VT/VF) (%) 2 (0.9) 0
Non-cardiac cause (%) 2 (0.9) 0
Renal replacement therapy (%) 3 (1.4) 0 0.004
2nd myocardial infarction (%) 1 (0.5) 0 0.098
Target revascularization (%) 1 (0.5) 2 (0.3) 0.797
Acute heart failure (%) 6 (2.8) 1 (1.0) 0.095
IABP (%) 13 (6.2) 16 (2.8) 0.025
Mechanical ventilation (%) 6 (2.8) 5 (0.9) 0.078
2nd angina (%) 7 (3.3) 37 (6.4) 0.094
Tachyarrhythmia (%) 7 (3.3) 12 (2.1) 0.316
Hypotension (%) 11 (5.3) 11 (1.9) 0.011
Cerebrovascular accident (%) 1 (0.5) 1 (0.2) 0.458
VT/VF, ventricular tachycardia/ventricular fibrillation; IABP, intra-aortic balloon pump.




HUA 5.38 1.99-15.58 0.001
Gender (female) 0.96 0.33-2.81 0.942
Age.75 y 3.55 1.21-10.42 0.021




Emergent PCI 3.66 1.40-9.55 0.008
LVEF,40% 1.86 0.50-6.87 0.351
Hypertension 1.89 0.64-5.59 0.250
Diabetes 0.61 0.18-2.02 0.416
ACEI/ARB 0.34 1.00-1.20 0.094
IABP 7.29 2.29-23.15 0.001
Exceeding MCD 1.84 0.31-11.10 0.504
Anemia 1.16 0.36-3.72 0.800
Diuretic usage 4.87 1.87-12.69 0.001
CrCl, Creatinine clearance; LVEF, left ventricular ejection fraction; ACEI/
ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor
blocker; IABP, intra-aortic balloon pump; MCD, maximum contrast dose
(mL) = (56body weight [kg]) divided by serum creatinine (mg/dL).
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PCI). Consequently, the incidence of CI-AKI in the present
study was lower than the incidence in previous studies
(14,28).
An understanding of the potential pathogenic role of uric
acid in acute renal failure (ARF) may be helpful for
understanding the relationship between HUA and the
progression of CI-AKI. Renal vasoconstriction is thought
to play a pathogenic role in ARF. The mechanism for the
uric acid–dependent decrease in renal blood flow seems to
be the loss of nitric oxide (NO) because the vasoconstriction
can be reversed with L-arginine (29). Furthermore, uric acid
strongly inhibits the release of NO from endothelial cells
(30,31). Uric acid increases the production of the chemotac-
tic factor monocyte chemoattractant protein-1 (MCP-1) in
vascular smooth muscle cells and enhances C-reactive
protein (CRP) synthesis in human vascular endothelial
and smooth muscle cells (31,32). Uric acid also inhibits
endothelial cell proliferation and migration (28) and causes
endothelial cell apoptosis (33).
When HUA was identified as a potentially modifiable risk
factor, we became interested in evaluating its connection
with CI-AKI and in-hospital adverse outcomes. Pakfetrat
et al. (34) found that serum uric acid levels did not differ
significantly between those patients with and without CI-
AKI (34). The authors explained that they failed to find a
difference because their study included a significant
number of patients with normal kidney function. Chen
et al. (35) found that HUA was an independent risk factor
for mortality from all causes, total cardiovascular disease,
and ischemic stroke in the general Taiwanese population, in
high-risk groups and potentially in low-risk groups (35). In
that study, HUA was significantly associated with increased
in-hospital mortality, and both CI-AKI and the need for
IABP therapy were significantly correlated with death.
However, HUA was not a significant and independent
predictor of in-hospital death. There were key differences
between our study and these other studies; for example, we
only recorded short-term outcomes (in-hospital vs. mean
follow-up of 8.2 years), and we used a relatively small
number of patients (788 vs. 146,900).
In another study of stage 3–4 CKD, HUA appeared to be
an independent risk factor for all-cause and cardiovascular
disease-induced mortality but not for kidney failure (36).
Kowalczyk et al. (37) evaluated the impact of HUA on
outcomes in patients undergoing invasive treatment for
impaired renal function and acute myocardial infarction
(AMI). They found that HUA was an independent risk
factor for death associated with an adjusted HR of 1.38 (95%
CI, 1.23–1.53) in patients with baseline kidney dysfunction
(p= 0.027), but there was no significant increase in risk for
patients with contrast-induced nephropathy (p= 0.08). The
exact pathophysiological mechanisms behind the relation-
ship are unknown. Uric acid, a marker of xanthine oxidase
(XO) activity, reflects the generation of reactive oxygen
species. In experimental studies, increased XO activity leads
to oxidative stress, which is associated with heart failure
after AMI (38). Published data show that both elevated and
decreased serum uric acid levels negatively impacted
patient outcomes, most likely because of the loss of the
plasma antioxidant properties of uric acid (39). In our study,
although most of the subjects had not experienced AMI and
had relatively normal renal function while undergoing PCI
(and thus had a relatively low risk of CI-AKI or death), we
also found a significant relationship between higher serum
uric acid levels and in-hospital death. However, the
proportion of HUA among the patients was higher than
the proportion in the study conducted by Kowalczyk et al.
(37) (68% [17/25] vs. 35.1% [343/693]).
In the multivariate analysis, after adjusting for potential
confounding factors (baseline creatinine clearance, LVEF,
contrast medium volume), age.75 years, emergent PCI, and
IABP therapy were retained in the final model. Because
acute kidney injury may result from hemodynamic instabil-
ity rather than from CI-AKI, performing elective PCI of non-
infarct-related arteries in patients with multivessel disease,
especially in older patients with multivessel coronary
disease, may be beneficial in protecting renal function.
Our results suggested that HUA was an independent,
modifiable risk factor for CI-AKI and that it significantly
increased the in-hospital adverse outcomes among the
patients who were undergoing coronary angiography.
Measuring serum uric acid levels before PCI seems to be a
useful method for assessing the risk of developing CI-AKI
and short-term clinical outcomes. In addition, an increase in
the serum uric acid level may serve as a disease biomarker
during the perioperative period. Physicians should be
encouraged to identify males whose uric acid levels
approached or exceeded 7 mg/dL and females whose levels
approached or exceeded 6 mg/dL, as they are the patients
at high risk for CI-AKI, and prophylactic measures should
be considered to preserve renal function. Another implica-
tion of this result is that uricosuric agents may be useful in
treating CI-AKI in patients who have undergone PCI or
other procedures. Setting a new marker for CI-AKI may
motivate large-scale future studies, which may find that
reducing the level of serum uric acid is an effective
prophylactic strategy for treating CI-AKI.
A recent study prospectively randomized 159 patients
with SCr.1.1 mg/dL undergoing cardiac catheterization
and interventions to receive allopurinol (300 mg, p.o.) 24 h
before the administration of a radiocontrast agent and
routine hydration (40). They found that CIN occurred in 6 of
80 patients (7.5%), and the median uric acid concentration
decreased from 6.8 mg/dL [3.5-13.5 mg/dL] to 6.3 mg/dL
[3.1-10.4 mg/dL] 48 h after administering contrast
(p,0.0001) in the control group, but none of the subjects
developed CIN in the allopurinol patients (p= 0.013), whose
mean uric acid concentration decreased from 6.8 mg/dL
[3.3-17.2] to 5.48 mg/dL [2.1-14.6 mg/dL]. Although the
authors concluded that the reduction in the prevalence of
CIN after administering allopurinol might have been caused
by the antioxidant capacity of allopurinol, the results clearly
showed a reduction in the uric acid concentration.
Study limitations
The current study has four limitations. First, it was a
prospective, observational study with a small sample size,
and it was conducted in a single center over a short
observation period. PCI operations and the decision to use
IABP, inotropic dugs, tirofiban, beta-blockers, ACE-inhibi-
tors, and diuretics were left to the discretion of cardiologists;
therefore, the results were influenced by operator bias. In
addition, to avoid introducing potential selection bias, we
used serum creatinine,1.5 mg/dl as our inclusion criteria
instead of creatinine clearance ,60 ml/min (using the
Cock-Croft-Gault formula to better assess kidney function).
Second, because of the variation in the measurement times,
we may have missed the peak levels of creatinine
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post-procedure. The variation and the failure to carry out
systematic measurements at the optimal times for determin-
ing the peak creatinine concentrations post-procedure may
have led us to underestimate the true incidence of
nephropathy in the current study population. Third,
information about the repeated measurements of serum
uric acid levels and body mass index were not available in
the original data set. Fourth, although some patients had
relatively normal SCr levels and did not receive the same
hydration strategy (i.e., the same duration and rate of
hydration) as those with elevated SCr values, these patients
may have actually exhibited some degree of renal damage,
and thus, the incidence of CI-AKI may be underestimated.
Our study found that CI-AKI might still develop even in
patients with normal SCr levels. HUA is a significant and
independent predictor of CI-AKI after PCI and results in a
significant increase in in-hospital mortality and the inci-
dence of CI-AKI requiring renal replacement therapy after
PCI. Thus, despite having normal baseline SCr levels,
patients with HUA, IABP, emergent PCI or older age
should receive more comprehensive renal prophylaxis to
reduce the occurrence of CI-AKI. The serum uric acid
measurements that are taken before PCI seem to be a useful
method for assessing the risk of developing CI-AKI and
short-term clinical outcomes. This observation may generate
hypotheses for future prospective trials that examine the
effectiveness of uric acid-lowering therapies for preventing
CI-AKI.
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